Translational control of ERK signaling through miRNA/4EHP-directed silencing

Translational control of ERK signaling through miRNA/4EHP-directed silencing

Seyed Mehdi Jafarnejad[1,a,b], Clément Chapat[1,a,b], Edna Matta-Camacho[a,b], Idit A. Gelbart[c], Geoffrey G. Hesketh[d], Meztli Arguello[a,b], Aitor Garzia[e], Sung-Hoon Kim[a,b], Jan Attig[f], Maayan Shapiro[a,b], Masahiro Morita[a,b,g], Arkady Khoutorsky[h], Tommy Alain[i], Christos G. Gkogkas[j], Noam Stern-Ginossar[c], Thomas Tuschl[e], Anne-Claude Gingras[d,k], Thomas Duchaine[a,b,2] and Nahum Sonenberg [a,b,2]

[1] These authors contributed equally to this manuscript

[a] Goodman Cancer Research Center, McGill University, Montreal, QC H3A 1A3, Canada

[b] Department of Biochemistry, McGill University, Montreal, QC H3A 1A3, Canada

[c] The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

[d] Centre for Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada

[e] Howard Hughes Medical Institute and Laboratory for RNA Molecular Biology, The Rockefeller University, 1230 York Ave, Box 186, New York, NY 10065

[f] The Francis Crick Institute, London, NW1 1AT, United Kingdom

[g] Present address: Department of Molecular Medicine and Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

[h] Department of Anesthesia and Alan Edwards Centre for Research on Pain, McGill University, H3A 0G1, Montréal, QC, Canada

[i] Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada

[j] Patrick Wild Centre, Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK

[k] Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada

[2] Correspondence: nahum.sonenberg@mcgill.ca, thomas.duchaine@mcgill.ca

Lead Contact: Nahum Sonenberg nahum.sonenberg@mcgill.ca,

ABSTRACT

MicroRNAs (miRNAs) exert a broad influence over gene expression by directing effector activities that impinge on translation and stability of mRNAs. We recently discovered that the cap-binding protein 4EHP is a key component of the mammalian miRNA-Induced Silencing Complex (miRISC), which mediates gene silencing. However, little is known about the mRNA repertoire that is controlled by the 4EHP/miRNA mechanism or its biological importance. Here, using ribosome profiling, we identify a subset of mRNAs that are translationally controlled by 4EHP. We show that the *Dusp6* mRNA, which encodes an ERK1/2 phosphatase, is translationally repressed by 4EHP and a specific miRNA, miR-145. This promotes ERK1/2 phosphorylation, resulting in augmented cell growth and reduced apoptosis. Our findings thus empirically define the integral role of translational repression in miRNA-induced gene silencing and reveal a critical function for this process in the control of the ERK signalling cascade in mammalian cells.

Keywords:

4EHP, miRNA, DUSP6, mRNA Translation, ERK, CCR4-NOT, miR-145

INTRODUCTION

mRNA translation commences with the binding of the eukaryotic initiation factor 4F (eIF4F) to the mRNA 5´ cap structure. eIF4F is a three-subunit complex composed of eIF4E, the m^7GpppN (cap)-interacting factor; eIF4G, a scaffolding protein, and eIF4A, a DEAD-box RNA helicase (Sonenberg & Hinnebusch, 2009). eIF4G also interacts with eIF3, through which it recruits the pre-initiation complex, comprised of the 40S ribosomal subunit and associated factors, to the mRNA. Binding of the mRNA 5´ cap by the 4E Homologous Protein (4EHP, encoded by *Eif4e2*), in contrast to eIF4E, impairs translation initiation (Cho et al., 2005; Morita et al., 2012; Rom et al., 1998a). 4EHP shares 28% sequence identity with eIF4E (Rom et al., 1998b) and is ubiquitously expressed, although it is 5–10 times less abundant than eIF4E in most cell types (Joshi, Cameron, & Jagus, 2004). 4EHP binds the cap with 30- to 100-fold weaker affinity than eIF4E, but its affinity is increased by interactions with other proteins such as 4E-T or post-translational modification (Chapat et al., 2017; Okumura, Zou, & Zhang, 2007). 4EHP is involved in translational repression directed by miRNAs (Chapat et al., 2017; Chen & Gao, 2017). The miRNA-Induced Silencing Complex (miRISC) recruits the CCR4–NOT complex to effect mRNA translational repression and decay (Jonas & Izaurralde, 2015). CCR4–NOT in turn recruits DDX6, 4E-T (eIF4E-Transporter; a conserved 4EHP/eIF4E-binding protein) and 4EHP to suppress cap-dependent mRNA translation (Chapat et al., 2017; Jonas & Izaurralde, 2015; Kamenska et al., 2014; Kamenska et al., 2016; Ozgur et al., 2015). However, which cellular mRNAs are targeted by 4EHP remains unknown.

The Extracellular signal-Regulated Kinases (ERK1/2) are important effectors of the highly conserved Mitogen-Activated Protein Kinase (MAPK) signalling pathways (Will et al., 2014). ERK signalling is controlled by the RAS GTPase, which activates RAF, a serine/threonine kinase. RAF phosphorylates and activates the kinase MEK, which in turn phosphorylates and activates the effector serine/threonine kinases ERK1/2. Activated ERK signalling elicits multiple outcomes, including transcriptional programs that control cellular functions such as cell proliferation (Aktas, Cai, & Cooper, 1997; Samatar & Poulikakos, 2014), apoptosis (Xia, Dickens, Raingeaud, Davis, & Greenberg, 1995) and mRNA translation (Fukunaga & Hunter, 1997).

Dual specificity phosphatase 6 (DUSP6), also called MAP kinase phosphatase-3 (MKP-3), is a highly specific phosphatase for ERK1/2 (Caunt & Keyse, 2013) and a key player in ERK signalling regulatory feedback loops (Camps et al., 1998; Eblaghie et al., 2003; Kolch, 2005; Mendoza, Er, & Blenis, 2011). *Dusp6*$^{-/-}$ mice exhibit increased ERK1/2 phosphorylation at Thr202/Tyr204 residues (C. Y. Li, D. A. Scott, E. Hatch, X. Y. Tian, & S. L. Mansour, 2007). DUSP6 expression is regulated transcriptionally (Bermudez et al., 2011b; Ekerot et al., 2008; Zhang et al., 2010), and post-transcriptionally by miRNAs (Banzhaf-Strathmann et al., 2014; Carson et al., 2017; Y. Gu et al., 2015) and RNA-binding proteins (Bermudez et al., 2011b; Galgano et al., 2008; Lee, Hook, Lamont, Wickens, & Kimble, 2006). Altered expression or activity of DUSP6 impacts on ERK signalling in various diseases such as cancer and neurological disorders (Banzhaf-Strathmann et al., 2014; Bermudez, Marchetti, Pages, & Gimond, 2008; Kawakami et al., 2003; C. Li, D. A. Scott, E. Hatch, X. Tian, & S. L. Mansour, 2007; Molina et al., 2009; Pfuhlmann et al., 2017; Shojaee et al., 2015).

Here, we employed ribosome profiling to identify a subset of mRNAs that are regulated by 4EHP. We discovered that *Dusp6* mRNA translation is repressed by a 4EHP/miRNA-dependent mechanism, which impacts on ERK1/2 phosphorylation, cell proliferation, and apoptosis. Our results underscore the biological importance of this translation repression mechanism, which is jointly orchestrated by miRNAs and 4EHP.

RESULTS

Enrichment for miRNA-binding sites in 4EHP-regulated mRNAs.

We recently discovered that 4EHP acts as a key component of the translational repression machinery, which is mobilized by miRNAs (Chapat et al., 2017). To identify mRNAs that are translationally controlled by 4EHP, we carried out ribosome profiling (Ingolia, Lareau, & Weissman, 2011) in wild-type (WT) and 4EHP knockout (4EHP-KO) mouse embryonic fibroblasts (MEFs) (Fig. S1A and B). This assay measures the ribosome occupancy of each mRNA by deep sequencing of ribosome-protected mRNA fragments (ribosome footprints; RFPs) (Ingolia et al., 2011). We used the Babel tool (Olshen et al., 2013; Stumpf, Moreno, Olshen, Taylor, & Ruggero, 2013) to detect significant changes in translation efficiency (abundance of RFPs independently of changes in the levels of their corresponding mRNAs). Translation was up-regulated for 117 mRNAs (hereafter referred to as upregulated mRNAs) in 4EHP-KO in comparison to WT cells, while translation was down-regulated for 167 mRNAs (Fig. 1A and **Supplementary file** 1). Whereas the translational up-regulation of the mRNAs can be explained by the activity of 4EHP as translational suppressor, translational downregulation may be the result of indirect adaptation effects following 4EHP loss.

We next analyzed the upregulated mRNAs for the presence of common sequence features in their UTRs or coding sequences. A significant positive correlation was observed between the length of the 3′ UTR and increased translation of the upregulated mRNAs in the 4EHP-KO cells (average of 2838.6, 2325.2, and 2016 nt for the up-regulated, unchanged and down-regulated mRNAs, respectively; p-value < 2.2e-16; Fig. 1B). We also found a less significant correlation (p= 1.742e-05; Fig. S1C) between the length of the 5′ UTR and increased mRNA translation efficiency in the 4EHP-KO cells. This indicates that mRNAs with longer 3′ UTR are more likely to be translationally repressed by 4EHP.

mRNAs with long 3′ UTR generally contain more miRNA-binding sites (Cheng, Bhardwaj, & Gerstein, 2009). We examined the number of miRNA-binding sites in the 3′ UTR of the upregulated mRNAs (Agarwal, Bell, Nam, & Bartel, 2015). mRNAs which exhibit increased translation in 4EHP-KO cells, contained significantly more predicted miRNA-binding sites (642.8, 518.4, and 442.6 for the up-regulated, unchanged and down-regulated mRNAs, respectively; p-values: 0.0004, Fig. 1C). We also calculated the density of miRNA-binding sites per 100-nucleotide of 3′ UTR and found 22.9, 22.1, and 21.1 for the up-regulated, unchanged and down-regulated mRNAs, respectively (p-values: 0.0063, Fig. 1D), indicating a greater density of miRNA-binding sites in 3′ UTR of upregulated mRNAs. These findings are in agreement with our previous report showing that 4EHP contributes to the translational silencing of miRNA targets by displacing eIF4E from the mRNA cap (Chapat et al., 2017). To verify that this mechanism affects the upregulated mRNAs, we performed RNA immunoprecipitation (RIP) with an anti-eIF4E antibody in WT and 4EHP-KO MEFs. IP resulted in specific

recovery of eIF4E (Fig. S1D). We examined the enrichment of the top 3 most translationally upregulated mRNAs in 4EHP-KO cells (*Tmed7, Slc35e1* and *Klhl21*; **Supplementary file** 1) among the eIF4E-bound mRNAs (Fig. 1E). *Slc35e1* and *Klhl21* but not *Tmed7* mRNAs were significantly enriched in eIF4E IP in 4EHP-KO cells in comparison with WT (Fig. 1E). *Lyar* and *Iqgap1*, which were among the most significant translationally down-regulated mRNAs, were not enriched in eIF4E IP as a consequence of 4EHP loss (Fig. 1F). These data show increased binding of eIF4E to the upregulated mRNAs in 4EHP-KO cells, and indicate that 4EHP blocks the physical association of its target mRNAs with eIF4E.

4EHP-depletion impinges on cell viability and ERK1/2 phosphorylation.

It was reported that while 4EHP expression is dispensable for growth in cell culture under physiological conditions, it is required under low oxygen conditions (Uniacke, Perera, Lachance, Francisco, & Lee, 2014). However, at variance with these findings, we found that 4EHP-KO MEFs grew significantly slower than their WT counterparts (48±3 % less on day 6; p=0.002) under standard cell culture conditions (5% CO_2 and 20% O_2) (Fig. 2A, S2A and S2B). Cell cycle analysis by FACS showed that the slow proliferation of 4EHP-KO cell populations is likely due to a decrease of the percentage of cells in S phase (30.3% and 21.4% for WT and KO cells, respectively; p=0.003), concomitant with an increase in the G0/G1 phase, compared with WT cells (50.2% and 57.7% for WT and KO cells, respectively; p=0.004, Fig. S2C). Consistently, depletion of 4EHP by shRNAs caused a dramatic reduction in proliferation of U251 (<90% at day 4; Fig. 2B, S2D), and U-87 human glioblastoma cell lines (Fig. S2E and S2F). Notably, FACS analysis showed

that unlike in MEFs, depletion of 4EHP in U251 cells increased the fraction of cells in sub-G1, which is associated with apoptosis (shCTR: 0.9%, sh4EHP#1: 15.5%, and sh4EHP#2: 11.4; Fig. 2C and S2G). Accordingly, 4EHP depletion in U251 cells also induced the accumulation of cleaved-PARP (C-PARP), a marker of apoptosis (Fig. S2D).

The signaling pathways RAS/RAF/MEK/ERK and PI3K/mTOR control cell proliferation, growth and apoptosis, either in parallel or by converging on common downstream factors (Cagnol & Chambard, 2010; Laplante & Sabatini, 2012; Mendoza et al., 2011). We determined the phosphorylation levels of ERK1/2 and ribosomal protein S6 (RPS6) as respective markers of RAS/RAF/MEK/ERK and PI3K/mTOR activity by western blot (WB) analysis. While RPS6 phosphorylation remained unchanged, ERK1/2 phosphorylation (Thr202/Tyr204; pERK) was more than 80% reduced in 4EHP-KO MEFs in comparison with WT (Fig 2D). A similar result was obtained in U251 cells upon 4EHP-knockdown (Fig. S2H). However, phosphorylation of MEK, the immediate upstream kinase of ERK1/2, remained unchanged in 4EHP-depleted cells (Fig. 2D and S2H). These results suggest that the expression or activity of a factor upstream of ERK1/2, which is independent of MEK, is deregulated in 4EHP-depleted cells.

4EHP represses *Dusp6* mRNA translation.

We interrogated the 4EHP-KO MEF ribosome profiling data to identify candidate genes that could explain the strong impact of 4EHP on ERK1/2 phosphorylation. Interestingly, the mRNA encoding DUSP6, a potent and specific ERK1/2 phosphatase (Caunt & Keyse, 2013), was among the most translationally up-regulated transcripts in 4EHP-KO MEFs as compared to WT MEFs, with no significant change in its mRNA levels (**Supplementary**

file 1). As expected, depletion of DUSP6 by shRNAs in U251 cells elicited ERK1/2 phosphorylation (Fig. S2I). To determine whether increased translation of *Dusp6* mRNA in 4EHP-KO MEFs is because of enhanced initiation, which is the rate limiting step in translation, we performed polysome profiling, which resolves mRNAs on a sucrose gradient according to the number of ribosomes with which they associate (Fig. S2J). While the distribution of the *Gapdh* mRNA along the sucrose gradient was similar in 4EHP-KO and WT cells, the *Dusp6* mRNA was shifted towards heavier fractions in the 4EHP-KO cells (Fig. 2E), demonstrating augmented initiation. Consistent with greater translation efficiency, DUSP6 protein amount was markedly increased in 4EHP-KO MEF as compared to WT (Fig. 2F). Up-regulation of DUSP6 protein level was also observed in U251 cells upon 4EHP knockdown in comparison with shCTR-treated cells (Fig. S2K). In contrast, expression of DUSP7, another member of the DUSP phosphatase family, was not affected by 4EHP depletion (Fig. S2L), attesting to the specificity of 4EHP loss for mRNA translation. 4EHP depletion did not affect the abundance (Fig. S2M) or stability of *Dusp6* mRNA (Fig. S2N). Importantly, restoring 4EHP expression in 4EHP-KO MEFs significantly reduced DUSP6 protein levels (~3-fold repression; Fig. 2G). Taken together, these data demonstrate that 4EHP controls expression of the ERK1/2 phosphatase DUSP6 at the level of mRNA translation initiation.

Dusp6 3´ UTR confers translational sensitivity to 4EHP.

To determine whether 4EHP regulates *Dusp6* translation by displacing eIF4E from the cap (Chapat et al., 2017; Cho et al., 2005), we examined the association of *Dusp6* mRNA with eIF4E in WT versus 4EHP-KO MEFs, using RIP. While *Dusp6* mRNA levels were

not significantly different between the WT and 4EHP-KO cells (Fig. 3A; for corresponding WB analysis, see Fig. S1D), an 8-fold enrichment of *Dusp6* mRNA was detected in eIF4E IP from 4EHP-KO MEF lysates, as compared to WT (Fig. 3A). As control, *Dusp7* mRNA was not enriched in eIF4E IP from 4EHP-KO MEFs lysates. These data lend further support to our model of displacement of eIF4E from the cap by 4EHP, and demonstrate that this mechanism causes translational repression of *Dusp6* mRNA.

3´ UTRs effect mRNA translation through trans-acting factors such as RNA-binding proteins (RBPs) and miRNAs (Szostak & Gebauer, 2013). DUSP6 expression is regulated by miRNAs including miR-145 (Y. F. Gu et al., 2015), miR-181a (Li et al., 2012), and the RBP PUM2 (Bermudez et al., 2011a), a homolog of *Drosophila* pumilio. We thus sought to study the role of the 3´ UTR of *Dusp6* mRNA in translational repression by 4EHP. To this end, 3´ rapid amplification of cDNA ends (3´ RACE) analysis was performed to amplify the 3´ UTR of *Dusp6* mRNA in U251 cells. A 1192-nucleotides segment was amplified (**Supplementary file** 2) and cloned into the psiCHECK-2 luciferase reporter vector. The resulting construct was transfected into HEK293T cells along with control siRNA (siCTR) or siRNA against 4EHP (si4EHP), or its partners CNOT1 (siCNOT1) and 4E-T (si4E-T). In the siCTR-transfected cells, the 3´ UTR of *Dusp6* mRNA caused a 3-fold repression in comparison with the backbone reporter alone (Fig. 3B). However, knockdown of 4EHP or its partners CNOT1 and 4E-T significantly de-repressed the psiCHECK-*Dusp6*-3´UTR reporter (38%, 49%, and 44% respectively as compared to siCTR; Fig. 3B), thus supporting the role of CCR4-NOT/4E-T/4EHP pathway in *Dusp6* mRNA translational repression. Consistent with the latter

239 results, knockdown of CNOT1 and CNOT9, two critical subunits of the CCR4-NOT
240 complex, also led to an increase of DUSP6 protein amounts in U251 cells (1.4 and 2.2-
241 folds, respectively; Fig. S3A).

242 We next mapped the repressive activity of 4EHP to elements of the 3´ UTR of *Dusp6*
243 mRNA. To this end, we sub-cloned six ~200 nt fragments of the 3´ UTR into the
244 psiCHECK-2 luciferase reporter (Fig. S3B). A segment harbouring both miR-145 and
245 miR-181a binding sites exerted the strongest repression on the reporter (1.5 fold; p=0001,
246 Fig. 3C), which was alleviated upon 4EHP knockdown (Fig. 3C). To identify which
247 miRNA is responsible for repression of *Dusp6* mRNA, we used specific inhibitors to
248 block miR-145, miR-181a, and miR-124 in U251 cells. While blocking miR-124 and
249 miR-181a did not affect DUSP6 expression, a miR-145 inhibitor increased DUSP6
250 accumulation to a similar degree as knockdown of 4EHP (Fig. 3D), without affecting the
251 stability of the *Dusp6* mRNA (Fig. S3C). We further investigated the effect of miR-145
252 inhibitor on a luciferase reporter with the full-length *Dusp6* 3´ UTR. Unlike the control
253 reporter, the expression of the reporter containing *Dusp6* 3´ UTR was significantly de-
254 repressed in the presence of miR-145 inhibitor (1.25 fold repression compared with 2.09
255 for mock inhibitor; Fig. 3E). Consistent with our observation that siRNA depletion of
256 4EHP in HEK293T cells de-repressed the *Dusp6* 3´ UTR reporter (Fig. 3B), silencing of
257 the same reporter was fully reversed in a 4EHP-KO HEK293 cells (Fig. 3E). No de-
258 repression by the miR-145 inhibitor was observed in 4EHP-KO HEK293 cells (Fig. 3E).
259 This confirms the requirement for 4EHP in miR-145-induced translational silencing of
260 *Dusp6* mRNA. Taken together, these data demonstrate that the *Dusp6* mRNA translation
261 is controlled by its 3´ UTR through the miRNA/CCR4-NOT/4E-T/4EHP pathway.

De-repression of DUSP6 impedes ERK activity and proliferation in 4EHP-depleted cells.

We next sought to determine the consequences of DUSP6 de-repression on ERK signaling and functions in 4EHP-KO MEFs. We used a selective small molecule inhibitor of DUSP6, 2-benzylidene-3-(cyclohexylamino)-1-Indanone hydrochloride (BCI) (Molina et al., 2009; Shojaee et al., 2015). Treatment of 4EHP-KO cells with BCI increased pERK1/2 to levels comparable with untreated WT cells within 30 minutes (Fig. 4A). Similar results were obtained with U251 cells expressing an shRNA against 4EHP (Fig. S4A). These data confirm that reduced ERK1/2 phosphorylation in 4EHP-depleted cells is due to increased DUSP6 activity. Next, we examined the consequence of DUSP6 inhibition on proliferation of 4EHP-depleted cells by using shRNAs to knockdown DUSP6 in WT and 4EHP-KO cells (Fig. S4B). While DUSP6 knockdown did not have a detectable impact on WT cells proliferation, depletion of DUSP6 in 4EHP-KO cells markedly augmented their proliferation (42% increase for sh4EHP#1 [p=0.007] and 65% increase for sh4EHP#2 [p=0.004] on day 4; Fig. 4B). This result demonstrates that the reduced proliferation of 4EHP-KO cells is at least partially due to de-repression of DUSP6.

Extracellular signals or mutations in *Ras* or *Raf*, which occur frequently in cancers, activate a phosphorylation cascade that results in phosphorylation and activation of ERK signaling (Samatar & Poulikakos, 2014). We examined whether 4EHP-depletion and the resulting increased DUSP6 expression could interfere with ERK1/2 phosphorylation in response to upstream activation of RAS. To this end, we expressed a constitutively active

mutant KRAS (G12V) (Prior, Lewis, & Mattos, 2012) and monitored ERK signaling by WB and proliferation assays. While ERK1/2 phosphorylation was increased by forced KRAS activity in WT MEFs, pERK levels remained unchanged in 4EHP-KO MEFs (Fig. 4C). Consistent with these results, WT MEFs proliferation was slightly increased upon enforced KRAS activity, but remained unaffected in 4EHP-KO MEFs (Fig. S4C).

Taken together, the data demonstrate that 4EHP up-regulates ERK1/2 phosphorylation by effecting the miRNA-induced translational repression of *Dusp6* mRNA, and that depletion of 4EHP limits ERK activation by upstream signaling (Fig. 4D, model).

DISCUSSION

We previously demonstrated that the cap-binding protein 4EHP acts as an effector of translational repression instigated by miRNAs. Here, we identify *Dusp6* mRNA as a functionally critical target of this silencing mechanism, which occurs in the absence of mRNA decay. Translational repression of *Dusp6* mRNA by the combined action of 4EHP and miR-145 down-regulates the MAPK/ERK signaling cascade and its output in cell proliferation and survival. The 4EHP/miRNA repression mechanism thus engenders important biological consequences in homeostasis and disease.

The relative contributions of translational repression and mRNA decay in miRNA-mediated silencing are in dispute. Several large-scale studies reported that mammalian miRNAs predominantly act by decreasing target mRNA levels (Baek et al., 2008; Eichhorn et al., 2014; Guo, Ingolia, Weissman, & Bartel, 2010), while others showed that miRNAs affect the expression of target genes by translation inhibition (Jin et al., 2017;

Selbach et al., 2008; Yang, Chaerkady, Beer, Mendell, & Pandey, 2009). It was convincingly demonstrated in *in vitro* and *in vivo* studies that translational repression precedes target mRNA decay (Bazzini, Lee, & Giraldez, 2012; Bethune, Artus-Revel, & Filipowicz, 2012; Djuranovic, Nahvi, & Green, 2012; Fabian et al., 2009; Mathonnet et al., 2007). Because of their intricate nature, the exact contribution of either aspect of miRNA-mediated silencing in biological decisions has remained elusive. Our data demonstrate that 4EHP effects miRNA-mediated translational repression of *Dusp6* mRNA, but not mRNA stability. The relative contribution of translational repression and mRNA degradation to miRNA-mediated silencing may thus depend on the target mRNAs and on the cellular context. Expression of miRISC core and accessory components, post-translational modifications, translation efficiency, RNA structure within a 3´ UTR, or interactions with RNA-binding proteins (RBPs) may interfere or promote miRISC activities (Cottrell, Chaudhari, Cohen, & Djuranovic, 2018; Cottrell, Szczesny, & Djuranovic, 2017; Kedde et al., 2010; Kundu, Fabian, Sonenberg, Bhattacharyya, & Filipowicz, 2012; Long et al., 2007). The RBPs PUM2 and TTP were implicated in the post-transcriptional repression of *Dusp6* mRNA, presumably in a CCR4-NOT-dependent mechanism (Bermudez et al., 2011b; Galgano et al., 2008). Since the abundance of RBPs varies in tissues and under pathological conditions, it is conceivable that the potency and the nature of the miRNA-mediated silencing mechanism are modulated by such RBPs.

Our study underscores the importance of translational control in regulation of the ERK signaling pathway. Indirect up-regulation of ERK1/2 phosphorylation by 4EHP, via repression of *Dusp6* translation, explains the diminished cell proliferation in 4EHP-KO MEF cells and apoptosis observed in 4EHP-depleted U251 and U87 cells. A notable

observation in our study is the impairment of the RAS/RAF/MEK/ERK pathway in 4EHP-depleted cells. Specifically, constitutively active RAS fails to increase ERK1/2 phosphorylation in 4EHP-KO MEFs. This can be explained by increased DUSP6 expression in 4EHP-KO cells, which effectively impairs phosphorylation of ERK1/2 downstream of RAS. Interestingly, over-expression of constitutively active RAS (Park, Lee, Shin, & Kim, 2014), or BRAF (Agrawal et al., 2014), also induces DUSP6 expression constituting a negative feedback loop. The feedback loop restrains the activity of the RAS/RAF/MEK/ERK pathway upon induction by stimuli (e.g. growth factors). Thus, increasing DUSP6 expression by inhibiting 4EHP can potentially repress ERK pathway activation. While several pharmacological approaches have been described for targeting eIF4E (Fischer, 2009; Graff et al., 2007), to date no specific inhibitor of 4EHP has been discovered. The elucidation of the crystal structures of 4EHP in association with its binding partners (Peter et al., 2017; Rosettani, Knapp, Vismara, Rusconi, & Cameron, 2007) may prove useful for this purpose.

Our ribosome profiling data strongly suggest that translational repression through miRNA/4EHP impacts on many other mRNAs. An interesting miRNA to revisit in light of this mechanism is let-7, which suppresses tumorigenesis by directly silencing RAS expression (Johnson et al., 2005). We had previously shown that 4EHP contributes to the translational repression activity of a reporter mRNA by let-7 miRNA (Chapat et al., 2017), but let-7 miRNA can also clearly instigate mRNA deadenylation and decay. The relative contributions of translation repression and mRNA decay in the function of miRNA/mRNA pairs may be further revealed by systematically addressing their epistasis with 4EHP in the relevant cellular context.

MATERIALS and METHODS

List of Antibodies, siRNAs and shRNAs

The following antibodies were used: rabbit anti-eIF4E2 (4EHP) (Genetex, GTX103977), mouse anti-eIF4E (BD Biosciences, 610270), rabbit anti-eIF4ENIF1 (4E-T; abcam, ab55881), rabbit anti-DDX6 (Bethyl Laboratories, A300-460A), rabbit anti-CNOT1 (Proteintech, 14276-1-AP), mouse anti-α-Tubulin (Santa Cruz, sc-23948), mouse anti-β-actin (Sigma, A5441), mouse anti-Flag (Sigma, F3165), rabbit anti-HA (Sigma, H6908), mouse anti-V5 tag (Invitrogen, R960-25), rabbit anti-PARP (Cell Signaling Cat# 9532S), rabbit anti-DUSP6 (abcam Cat# ab76310), rabbit anti-DUSP7 (abcam Cat# ab100921),), rabbit anti-CNOT9 (RQCD1) (Proteintech Cat# 22503-1-AP), rabbit anti-CNOT2 (Cell Signaling Cat# 6955S), rabbit anti-phospho-ERK1/2 (Thr202/Tyr204; Cell Signaling Cat#4370), mouse anti-MEK1/2 (Cell Signaling Cat# 4694S), rabbit anti-phospho-MEK1/2 (Ser217/221; Cell Signaling Cat# 9121S), rabbit anti-phospho-RPS6 (Ser240/244) (Cell Signaling Cat# 2215), and mouse anti-RPS6 (C-8).

The following siRNA and shRNAs were used: ON-TARGETplus Non-targeting Control Pool (Dharmacon, D-001810-10-05), 4EHP siRNA SMARTpool (Dharmacon, L-019870-01), eIF4ENIF1 (4E-T) siRNA SMARTpool (Dharmacon, L-013237-01), Non-Targeting shRNA Controls (Sigma, SHC002), and EIF4E2 shRNA (Sigma, TRCN0000152006).

Cell lines and culture conditions

MEFs, U251 (ATCC), U87 (ATCC), and HEK293T (Thermo Fisher Scientific) cells were maintained in DMEM supplemented with 10% foetal bovine serum and penicillin/streptomycin in a humidified atmosphere of 5% CO2 at 37°C. Control and 4EHP-knockout Flp-In T-REx 293 cells (HEK293, Thermo Fisher Scientific) were grown in high glucose DMEM (Thermo Fisher Scientific, 11965118) supplemented with 10% v/v FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 100 µg/ml zeocin and 15 µg/ml blasticidin. U251, U87, and HEK293T were tested for presence of mycoplasma contamination by LookOut® Mycoplasma PCR Detection Kit (SIGMA, MP0035). Presence of mycoplasma in HEK293 cells was tested and dismissed by mRNA-Seq as previously described (Garzia et al., 2017).

Inhibition of miRNA activity

The following miRNA inhibitors (Thermo Fisher Scientific, 4464084) were used: anti-miR-124 (MH10421), anti-miR-145 (MH11480), anti-miR-181 (MH10691) and mirVana negative control (4464076). 200,000 U251 cells were plated in a 6-well plate and transfected with a final concentration of 50 nM of each miRNA inhibitor for 72 h using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.

Lentivirus production

$8x10^6$ 293FT (Thermo Fisher Scientific, R70007) cells were cultured in a 10-cm dish for 24 h in high glucose DMEM supplemented with 10% v/v FBS. Medium was replaced by OptiMEM (Thermo Fisher Scientific, 51985091) 30 min before transfection. Lentivirus particles were produced by transfecting the HEK293FT cells using Lipofectamine 2000 and 10 µg shRNA plasmid, 6.5 µg psPAX2 (Addgene, plasmid 12260) and 3.5 µg

pMD2.G (Addgene, plasmid 12259) packaging plasmids. 5 h post-transfection, the medium was replaced with fresh high glucose DMEM supplemented with 10% v/v FBS. Supernatant was collected at 48 h post-transfection, replaced with fresh medium and collected after 24 h. Viral particles were cleared by filtration (45 µm; Fisher Scientific, 09-720-005) and virus titer was measured by colony formation assay using 293FT cells. The multiplicity of infection (MOI) was adjusted to ~5. Virus solution was stored at -80ºC without cryopreservative in 1 ml aliquots or used to infect the cells directly in the presence of 6 µg/ml polybrene (Sigma, H9268).

CRISPR-Cas9 genome engineering for generating 4EHP knockout HEK293 cell line

CRISPR-Cas9-mediated genome editing of Flp-In T-REx HEK293 cells was performed as previously described (Ran et al., 2013). Two small guide RNAs (sgRNAs) cognate to the coding region of 4EHP gene: 5´-CAACAAGTTCGACGCGTGAG and 5´-TGAGCTCGTGGGACGGCCGG were designed. The top and bottom strands of each designed sgRNA were annealed creating overhangs for cloning of the guide sequence oligos into pSpCas9(BB)-2A-GFP (Addgene, PX458, Plasmid #48138) by BbsI digestion. To generate gene knockout Flp-In T-REx HEK293 cells, we transfected 130.000 cells with the corresponding guide sequence containing pSpCas9(BB)-2A-GFP plasmid. 24 hours after transfection, GFP-positive single cells were sorted by FACS into 96-well plates and cultivated until colonies were obtained. Clonal cell lines were analyzed by WB for protein depletion as well as by PCR-genotyping. The following primers were used for the PCR-genotyping: sense primer1, 5´-GCCGCCCTGAGCTGGCGTCCC; anti-sense primer1, 5´-CGGCACAGCCACCCCTCCCCC; sense primer2, 5´-

GCAGAATCTTTGGCACATTGCAGATAGTTGAGG; anti-sense primer2, 5´-GCCCTTCTGATCAACTCTACAATTCTCATATTTGTTGATACC. PCR products were cloned using the Zero Blunt PCR Cloning Kit (Thermo Fisher Scientific, K270040) and 10 clones sequenced per cell line.

Real-Time RT-qPCR

1 µg of DNase I-treated total RNA, purified using the TRI-Reagent, was reverse-transcribed using 100 ng of random primers following the Superscript III (Invitrogen) protocol. Real time PCR was performed with SYBR Green master mix (iQ; Biorad) in a real-time PCR detection system (Mastercycler *Realplex*, Eppendorf). Mean values of triplicate measurements were calculated according to the –ΔΔCt quantification method, and were normalized against the expression of the indicated mRNA. Specificity was confirmed by analyzing the melting curves of PCR products. RT-qPCR results were repeated at least three times in independent experiments and representative data sets are shown. Sequences of the used primers are listed in the **Supplementary file** 3.

3´ rapid amplification of cDNA ends (3´ RACE) analysis

3′ RACE was performed with the SMARTer RACE 5′/3′ kit (Clontech, Cat # 634858). 1 µg of total RNAs extracted from U251 cells was treated with DNase I (Fermentas) and cDNA was generated by the SMARTScribe Reverse Transcriptase (Clontech), according to the manufacturer's instructions. The resultant cDNA was used for PCR amplification using the human *DUSP6* gene-specific forward primers (GSPs) (**Supplementary file** 2) together with a common Universal Reverse Primer (UPM), provided by the manufacturer. PCR products were resolved by agarose gel electrophoresis and all visible

bands were excised and digested by restriction enzymes followed by cloning into the PUC19 vector provided by the manufacturer and sequenced by Sanger sequencing.

RNA immunoprecipitation (RIP)

RIP was performed as described previously (Thoreen et al., 2012) with minor modifications. WT and 4EHP-KO MEFs were seeded in 3x15 cm plates (at $10x10^6$ cells per plate) and incubated overnight. Cells were lysed in lysis buffer A (50 mM HEPES-KOH (pH: 7.4), 2 mM EDTA, 10 mM pyrophosphate, 10 mM beta-glycerophosphate, 40 mM NaCl, 1% Trition X-100 and one tablet of EDTA-free protease inhibitors (Roche)) containing 40 U/ml SuperaseIn. Insoluble material was removed by centrifugation at 20,000xg for 5 min at 4^{o}C. Protein concentration was measured by Bradford assay and 2 mg of lysate was pre-cleared by incubating with 50 µl of 50% protein G agarose fast flow beads (EMD Millipore, 16-266) for 2 h at 4ºC with gentle agitation. The cleared lysates were collected by centrifugation at 3,000xg for 1 min at 4ºC and collecting the supernatant. In parallel 2 µg of anti-eIF4E antibody was incubated with 50 µl of 50% protein G agarose fast flow beads for on an end-over-end rotator for 2 h at 4ºC. For IP, the pre-cleared lysates were incubated with the antibody + bead mixture, in 1 ml total volume on an end-over-end rotator for 2 h at 4ºC. The precipitated beads were then washed 3x with 1 ml buffer A, twice with buffer B (15 mM HEPES-KOH (pH 7.4), 7.5 mM MgCl2, 100 mM KCl, 2 mM DTT and 1.0% Triton X-100), and resuspended in 100 µl buffer B. 10 µl of the final mix was used for WB and the remaining was used for RNA extraction.

Cycloheximide treatment and hypotonic cell lysis

Cells were pretreated with cycloheximide (Bioshop Canada Cat#CYC003) (100 µg/ml) for 5 min, and lysed in hypotonic buffer (5 mM Tris-HCl (pH 7.5), 2.5 mM MgCl2, 1.5 mM KCl, 1x protease inhibitor cocktail (EDTA-free), 100 µg/ml cycloheximide, 2 mM DTT, 200 U/ml RNaseIn, 0.5% (v/w) Triton X-100, and 0.5% (v/w) Sodium Deoxycholate), to isolate the polysomes.

Collection of ribosome footprints (RFPs)

Ribosome profiling was performed as described (Ingolia, Brar, Rouskin, McGeachy, & Weissman, 2012), with minor modifications. Briefly, 500 µg of the ribonucleoproteins were subjected to ribosome footprinting by RNase I treatment at 4^{o}C for 45 min with end-over-end rotation. Monosomes were pelleted by ultracentrifugation in a 34% sucrose cushion at 70,000xrpm for 3h and RNA fragments were extracted twice with acid phenol, once with chloroform, and precipitated with isopropanol in the presence of NaOAc and GlycoBlue. Purified RNA was resolved on a denaturing 15% polyacrylamide-urea gel and the section corresponding to 28-32 nucleotides containing the RFPs was excised, eluted, and precipitated by isopropanol.

Random RNA fragmentation and mRNA-Seq

100 µg of cytoplasmic RNA was used for mRNA-Seq analysis. Poly (A)+ mRNAs were purified using magnetic oligo-dT DynaBeads (Invitrogen) according to the manufacturer's instructions. Purified RNA was eluted from the beads and mixed with an equal volume of 2X alkaline fragmentation solution (2 mM EDTA, 10 mM Na2CO3, 90 mM NaHCO3, pH 9.2) and incubated for 20 min at 95^{o}C. Fragmentation reactions were mixed with stop/precipitation solution (300 mM NaOAc pH 5.5 and GlycoBlue),

followed by isopropanol precipitation. Fragmented mRNA was size-selected on a denaturing 10% polyacrylamide-urea gel and the area corresponding to 35-50 nucleotides was excised, eluted, and precipitated with isopropanol.

Library preparation and sequencing

Fragmented mRNAs and RFPs were dephosphorylated using T4 polynucleotide kinase (New England Biolabs). Denatured fragments were resuspended in 10 mM Tris (pH 7) and quantified using the Bio-Analyzer Small RNA assay (Agilent). 10 pmol of RNA was ligated to the 3′-adaptor with T4 RNA ligase 1 (New England Biolabs) for 2 h at 37°C. Reverse transcription was carried out using oNTI223 adapter (Illumina) and SuperScript III reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Products were separated from the empty adaptor on a 10% polyacrylamide Tris/Borate/EDTA-urea (TBE-urea) gel and circularized by CircLigase (Epicentre). Ribosomal RNA amounts were reduced by subtractive hybridization using biotinylated rDNA complementary oligos (Ingolia et al., 2012). The mRNA and ribosome-footprint libraries were amplified by PCR (12 cycles) using indexed primers and quantified using the Agilent BioAnalyzer High-Sensitivity assay. DNA was then sequenced on the HiSeq 2000 platform with read length of 50 nucleotides (SR50) according to the manufacturer's instructions, with sequencing primer oNTI202 (5CGACAGGTTCAGAGTTCTACAGTCCGACGATC).

Analysis of Ribosome profiling data

Prior to alignment, linker and polyA sequences were removed from the 3´ ends of reads. Bowtie v0.12.7 (allowing up to 2 mismatches) was used to perform the alignments. First,

reads that aligned to rRNA sequences were discarded. All remaining reads were aligned to the mouse genome (mm10). Finally, still-unaligned reads were aligned to the mouse known canonical transcriptome that includes splice junctions. Reads with unique alignments were used to compute the total number of reads at each position. Footprints and mRNA densities were calculated in units of reads per kilobase per million (RPKM) to normalize for gene length and total reads per sequencing run. The expression patterns were examined for genes that had more than 150 uniquely aligned reads of mRNA and footprints in one of the samples. The Babel computational framework was used to quantitatively evaluate if there are genes that are differently translated in KO cells (1). The 5´ and 3´ UTRs were obtained from the UCSC Genome Browser. For translationally induced or repressed genes the length of 5´ and 3´ UTRs were calculated and compared using Welch Two Sample t-test. Predicted miRNA sites were retrieved from TargetScanMouse. Both conserved and non-conserved sites were taken into account. The number of miRNA sites per 100 bp of 3´ UTR was calculated using the 3´ UTR lengths published on TargetScanMouse. The GEO accession numbers for the sequencing data reported in this paper is GSE107826.

RNA stability assay

300,000 cells were plated in 6-well plates and 5 μg/ml actinomycin D (Sigma) was added to the culture medium at the indicated times. RNA was isolated by using Tri Reagent (Sigma-Aldrich), according to the manufacturer's protocol and the stability of the indicated transcript was measured by RT-qPCR with the primers indicated in **Supplementary file** 3.

Preparation of reporter constructs

To generate luciferase reporter plasmids, a modified version of psiCHECK-2 (Promega) containing the Gateway cassette C.1 (Invitrogen) at the 3´ end of the firefly luciferase (*F-Luc*) gene was used as described before (Suffert et al., 2011). The 3′ UTR sequence of *Dusp6* mRNA inserted in the PUC19 vector was obtained from the U251 cells by 3´ RACE assay. The *att*B-Dusp6 fragment was obtained by PCR with the primers indicated in **Supplementary file** 3, cloned into pDONR/Zeo (Invitrogen) and recombined in the modified psiCHECK-2 vector by Gateway cloning. The fragments of the 3′ UTR of *Dusp6* were obtained by PCR from the psiCHECK-Dusp6 3'UTR vector and inserted as XhoI-NotI fragments into the psiCHECK-2 vector at the 3′-end of the *Renilla* luciferase gene (*R-Luc*). Sequences of the used primers are listed in the **Supplementary file** 3.

Luciferase reporter assay

HEK293T and U251 cells (15000 cell/well) were co-transfected in a 24-well plate with 10 ng psiCHECK-Dusp6 3´ UTR. For 4EHP knockdown, $4x10^6$ cells were plated in a 10 cm culture dish and transfected with a final concentration of 25 nM of siRNA duplexes using Lipofectamine 2000 according to the manufacturer's instructions. After 24 h, cells were plated in a 24-well plate and transfected a second time with the psiCHECK vectors as described above. Cells were lysed 24 h after transfection. Luciferase activities were measured with the Dual-Luciferase Reporter Assay System (Promega) in a GloMax 20/20 luminometer (Promega). For experiments with miRNA inhibitors, HEK293 cells were co-transfected in a 24-well plate with 10 ng psiCHECK-Dusp6 3´ UTR and miRNA inhibitors were added to the transfection mixture at a final concentration of 50 nM.

ACKNOWLEDGMENTS

We thank Owen Cheng for technical assistance; Joshua Dunn, and Nadeem Siddiqui for discussions and Chris Rouya for reagents. The work was supported by a Canadian Institute of Health Research (CIHR) Foundation grant FDN-148423 (to N.S.), FDN-143301 (to A.-C.G.), and MOP-123352 (to T.F.D.), the Fonds de la Rercherche en Santé du Québec (FRSQ), Chercheur-Boursier Senior salary award (T.F.D.), and Natural Sciences and Engineering Research Council of Canada (NSERC; RGPIN-2014-06434 to A.-C.G.). S.M.J. is a recipient of McLaughlin and CIHR Postdoctoral fellowships. C.C. is supported by FRQS and Fondation pour la Recherche Médicale (FRM) postdoctoral fellowships. G.G.H. was supported by a Parkinson Canada Basic Research Fellowship. A-C.G. is the Canada Research Chair in Functional Proteomics.

COMPETING INTERESTS: The authors declare no competing financial interest.

REFRENCES

Agarwal, V., Bell, G. W., Nam, J. W., & Bartel, D. P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. *Elife, 4*. doi:10.7554/eLife.05005

Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., . . . Network, C. G. A. R. (2014). Integrated Genomic Characterization of Papillary Thyroid Carcinoma. *Cell, 159*(3), 676-690. doi:10.1016/j.cell.2014.09.050

Aktas, H., Cai, H., & Cooper, G. M. (1997). Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. *Mol Cell Biol, 17*(7), 3850-3857.

Baek, D., Villen, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008). The impact of microRNAs on protein output. *Nature, 455*(7209), 64-71. doi:10.1038/nature07242

Banzhaf-Strathmann, J., Benito, E., May, S., Arzberger, T., Tahirovic, S., Kretzschmar, H., . . . Edbauer, D. (2014). MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease. *EMBO J, 33*(15), 1667-1680. doi:10.15252/embj.201387576

579 Bazzini, A. A., Lee, M. T., & Giraldez, A. J. (2012). Ribosome profiling shows that miR-430
580 reduces translation before causing mRNA decay in zebrafish. *Science, 336*(6078),
581 233-237. doi:10.1126/science.1215704
582 Bermudez, O., Jouandin, P., Rottier, J., Bourcier, C., Pages, G., & Gimond, C. (2011a). Post-
583 Transcriptional Regulation of the DUSP6/MKP-3 Phosphatase by MEK/ERK
584 Signaling and Hypoxia. *Journal of Cellular Physiology, 226*(1), 276-284.
585 doi:10.1002/jcp.22339
586 Bermudez, O., Jouandin, P., Rottier, J., Bourcier, C., Pages, G., & Gimond, C. (2011b). Post-
587 transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling
588 and hypoxia. *J Cell Physiol, 226*(1), 276-284. doi:10.1002/jcp.22339
589 Bermudez, O., Marchetti, S., Pages, G., & Gimond, C. (2008). Post-translational regulation of
590 the ERK phosphatase DUSP6/MKP3 by the mTOR pathway. *Oncogene, 27*(26), 3685-
591 3691. doi:10.1038/sj.onc.1211040
592 Bethune, J., Artus-Revel, C. G., & Filipowicz, W. (2012). Kinetic analysis reveals successive
593 steps leading to miRNA-mediated silencing in mammalian cells. *EMBO Rep, 13*(8),
594 716-723. doi:10.1038/embor.2012.82
595 Cagnol, S., & Chambard, J. C. (2010). ERK and cell death: mechanisms of ERK-induced cell
596 death--apoptosis, autophagy and senescence. *FEBS J, 277*(1), 2-21.
597 doi:10.1111/j.1742-4658.2009.07366.x
598 Camps, M., Nichols, A., Gillieron, C., Antonsson, B., Muda, M., Chabert, C., . . . Arkinstall, S.
599 (1998). Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated
600 protein kinase. *Science, 280*(5367), 1262-1265.
601 Carson, W. F. t., Salter-Green, S. E., Scola, M. M., Joshi, A., Gallagher, K. A., & Kunkel, S. L.
602 (2017). Enhancement of macrophage inflammatory responses by CCL2 is correlated
603 with increased miR-9 expression and downregulation of the ERK1/2 phosphatase
604 Dusp6. *Cell Immunol, 314*, 63-72. doi:10.1016/j.cellimm.2017.02.005
605 Caunt, C. J., & Keyse, S. M. (2013). Dual-specificity MAP kinase phosphatases (MKPs):
606 shaping the outcome of MAP kinase signalling. *FEBS J, 280*(2), 489-504.
607 doi:10.1111/j.1742-4658.2012.08716.x
608 Chapat, C., Jafarnejad, S. M., Matta-Camacho, E., Hesketh, G. G., Gelbart, I. A., Attig, J., . . .
609 Sonenberg, N. (2017). Cap-binding protein 4EHP effects translation silencing by
610 microRNAs. *Proc Natl Acad Sci U S A, 114*(21), 5425-5430.
611 doi:10.1073/pnas.1701488114
612 Chen, S., & Gao, G. (2017). MicroRNAs recruit eIF4E2 to repress translation of target mRNAs.
613 *Protein Cell, 8*(10), 750-761. doi:10.1007/s13238-017-0444-0
614 Cheng, C., Bhardwaj, N., & Gerstein, M. (2009). The relationship between the evolution of
615 microRNA targets and the length of their UTRs. *Bmc Genomics, 10*. doi:Artn 431
616 10.1186/1471-2164-10-431
617 Cho, P. F., Poulin, F., Cho-Park, Y. A., Cho-Park, I. B., Chicoine, J. D., Lasko, P., & Sonenberg, N.
618 (2005). A new paradigm for translational control: Inhibition via 5 '-3 ' mRNA
619 tethering by Bicoid and the eIF4E cognate 4EHP. *Cell, 121*(3), 411-423.
620 doi:10.1016/j.cell.2005.02.024
621 Cottrell, K. A., Chaudhari, H. G., Cohen, B. A., & Djuranovic, S. (2018). PTRE-seq reveals
622 mechanism and interactions of RNA binding proteins and miRNAs. *Nat Commun,*
623 *9*(1), 301. doi:10.1038/s41467-017-02745-0
624 Cottrell, K. A., Szczesny, P., & Djuranovic, S. (2017). Translation efficiency is a determinant of
625 the magnitude of miRNA-mediated repression. *Sci Rep, 7*(1), 14884.
626 doi:10.1038/s41598-017-13851-w

627 Djuranovic, S., Nahvi, A., & Green, R. (2012). miRNA-mediated gene silencing by
628 translational repression followed by mRNA deadenylation and decay. *Science,*
629 *336*(6078), 237-240. doi:10.1126/science.1215691
630 Eblaghie, M. C., Lunn, J. S., Dickinson, R. J., Munsterberg, A. E., Sanz-Ezquerro, J. J., Farrell, E.
631 R., . . . Tickle, C. (2003). Negative feedback regulation of FGF signaling levels by
632 Pyst1/MKP3 in chick embryos. *Curr Biol, 13*(12), 1009-1018.
633 Eichhorn, S. W., Guo, H., McGeary, S. E., Rodriguez-Mias, R. A., Shin, C., Baek, D., . . . Bartel, D.
634 P. (2014). mRNA destabilization is the dominant effect of mammalian microRNAs by
635 the time substantial repression ensues. *Mol Cell, 56*(1), 104-115.
636 doi:10.1016/j.molcel.2014.08.028
637 Ekerot, M., Stavridis, M. P., Delavaine, L., Mitchell, M. P., Staples, C., Owens, D. M., . . . Keyse, S.
638 M. (2008). Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is
639 driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the
640 DUSP6/MKP-3 gene promoter. *Biochem J, 412*(2), 287-298.
641 doi:10.1042/BJ20071512
642 Fabian, M. R., Mathonnet, G., Sundermeier, T., Mathys, H., Zipprich, J. T., Svitkin, Y. V., . . .
643 Sonenberg, N. (2009). Mammalian miRNA RISC recruits CAF1 and PABP to affect
644 PABP-dependent deadenylation. *Mol Cell, 35*(6), 868-880.
645 doi:10.1016/j.molcel.2009.08.004
646 Fischer, P. M. (2009). Cap in hand: targeting eIF4E. *Cell Cycle, 8*(16), 2535-2541.
647 doi:10.4161/cc.8.16.9301
648 Fukunaga, R., & Hunter, T. (1997). MNK1, a new MAP kinase-activated protein kinase,
649 isolated by a novel expression screening method for identifying protein kinase
650 substrates. *EMBO J, 16*(8), 1921-1933. doi:10.1093/emboj/16.8.1921
651 Galgano, A., Forrer, M., Jaskiewicz, L., Kanitz, A., Zavolan, M., & Gerber, A. P. (2008).
652 Comparative analysis of mRNA targets for human PUF-family proteins suggests
653 extensive interaction with the miRNA regulatory system. *PLoS One, 3*(9), e3164.
654 doi:10.1371/journal.pone.0003164
655 Garzia, A., Jafarnejad, S. M., Meyer, C., Chapat, C., Gogakos, T., Morozov, P., . . . Sonenberg, N.
656 (2017). The E3 ubiquitin ligase and RNA-binding protein ZNF598 orchestrates
657 ribosome quality control of premature polyadenylated mRNAs. *Nat Commun, 8*,
658 16056. doi:10.1038/ncomms16056
659 Graff, J. R., Konicek, B. W., Vincent, T. M., Lynch, R. L., Monteith, D., Weir, S. N., . . . Marcusson,
660 E. G. (2007). Therapeutic suppression of translation initiation factor eIF4E
661 expression reduces tumor growth without toxicity. *Journal of Clinical Investigation,*
662 *117*(9), 2638-2648. doi:10.1172/Jci32044
663 Gu, Y., Li, D., Luo, Q., Wei, C., Song, H., Hua, K., . . . Fang, L. (2015). MicroRNA-145 inhibits
664 human papillary cancer TPC1 cell proliferation by targeting DUSP6. *Int J Clin Exp*
665 *Med, 8*(6), 8590-8598.
666 Gu, Y. F., Li, D. F., Luo, Q. F., Wei, C. K., Song, H. M., Hua, K. Y., . . . Fang, L. (2015). Original
667 Article MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by
668 targeting DUSP6. *International Journal of Clinical and Experimental Medicine, 8*(6),
669 8590-8598.
670 Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010). Mammalian microRNAs
671 predominantly act to decrease target mRNA levels. *Nature, 466*(7308), 835-840.
672 doi:10.1038/nature09267
673 Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., & Weissman, J. S. (2012). The
674 ribosome profiling strategy for monitoring translation in vivo by deep sequencing of
675 ribosome-protected mRNA fragments. *Nat Protoc, 7*(8), 1534-1550.
676 doi:10.1038/nprot.2012.086

Ingolia, N. T., Lareau, L. F., & Weissman, J. S. (2011). Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. *Cell, 147*(4), 789-802. doi:10.1016/j.cell.2011.10.002

Jin, H. Y., Oda, H., Chen, P., Yang, C., Zhou, X., Kang, S. G., . . . Xiao, C. (2017). Differential Sensitivity of Target Genes to Translational Repression by miR-17~92. *PLoS Genet, 13*(2), e1006623. doi:10.1371/journal.pgen.1006623

Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., . . . Slack, F. J. (2005). RAS is regulated by the let-7 MicroRNA family. *Cell, 120*(5), 635-647. doi:10.1016/j.cell.2005.01.014

Jonas, S., & Izaurralde, E. (2015). Towards a molecular understanding of microRNA-mediated gene silencing. *Nat Rev Genet, 16*(7), 421-433. doi:10.1038/nrg3965

Joshi, B., Cameron, A., & Jagus, R. (2004). Characterization of mammalian eIF4E-family members. *Eur J Biochem, 271*(11), 2189-2203. doi:10.1111/j.1432-1033.2004.04149.x

Kamenska, A., Lu, W. T., Kubacka, D., Broomhead, H., Minshall, N., Bushell, M., & Standart, N. (2014). Human 4E-T represses translation of bound mRNAs and enhances microRNA-mediated silencing. *Nucleic Acids Res, 42*(5), 3298-3313. doi:10.1093/nar/gkt1265

Kamenska, A., Simpson, C., Vindry, C., Broomhead, H., Benard, M., Ernoult-Lange, M., . . . Standart, N. (2016). The DDX6-4E-T interaction mediates translational repression and P-body assembly. *Nucleic Acids Res, 44*(13), 6318-6334. doi:10.1093/nar/gkw565

Kawakami, Y., Rodriguez-Leon, J., Koth, C. M., Buscher, D., Itoh, T., Raya, A., . . . Izpisua Belmonte, J. C. (2003). MKP3 mediates the cellular response to FGF8 signalling in the vertebrate limb. *Nat Cell Biol, 5*(6), 513-519. doi:10.1038/ncb989

Kedde, M., van Kouwenhove, M., Zwart, W., Oude Vrielink, J. A., Elkon, R., & Agami, R. (2010). A Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibility. *Nat Cell Biol, 12*(10), 1014-1020. doi:10.1038/ncb2105

Kolch, W. (2005). Coordinating ERK/MAPK signalling through scaffolds and inhibitors. *Nat Rev Mol Cell Biol, 6*(11), 827-837. doi:10.1038/nrm1743

Kundu, P., Fabian, M. R., Sonenberg, N., Bhattacharyya, S. N., & Filipowicz, W. (2012). HuR protein attenuates miRNA-mediated repression by promoting miRISC dissociation from the target RNA. *Nucleic Acids Res, 40*(11), 5088-5100. doi:10.1093/nar/gks148

Laplante, M., & Sabatini, D. M. (2012). mTOR signaling in growth control and disease. *Cell, 149*(2), 274-293. doi:10.1016/j.cell.2012.03.017

Lee, M. H., Hook, B., Lamont, L. B., Wickens, M., & Kimble, J. (2006). LIP-1 phosphatase controls the extent of germline proliferation in Caenorhabditis elegans. *EMBO J, 25*(1), 88-96. doi:10.1038/sj.emboj.7600901

Li, C., Scott, D. A., Hatch, E., Tian, X., & Mansour, S. L. (2007). Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. *Development, 134*(1), 167-176. doi:10.1242/dev.02701

Li, C. Y., Scott, D. A., Hatch, E., Tian, X. Y., & Mansour, S. L. (2007). Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. *Development, 134*(1), 167-176. doi:10.1242/dev.02701

Li, G. J., Yu, M. C., Lee, W. W., Tsang, M., Krishnan, E., Weyand, C. M., & Goronzy, J. J. (2012). Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. *Nature Medicine, 18*(10), 1518-U1113. doi:10.1038/nm.2963

Long, D., Lee, R., Williams, P., Chan, C. Y., Ambros, V., & Ding, Y. (2007). Potent effect of target structure on microRNA function. *Nat Struct Mol Biol, 14*(4), 287-294. doi:10.1038/nsmb1226

Mathonnet, G., Fabian, M. R., Svitkin, Y. V., Parsyan, A., Huck, L., Murata, T., . . . Sonenberg, N. (2007). MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. *Science, 317*(5845), 1764-1767. doi:10.1126/science.1146067

Mendoza, M. C., Er, E. E., & Blenis, J. (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. *Trends Biochem Sci, 36*(6), 320-328. doi:10.1016/j.tibs.2011.03.006

Molina, G., Vogt, A., Bakan, A., Dai, W. X., de Oliveira, P. Q., Znosko, W., . . . Tsang, M. (2009). Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. *Nature Chemical Biology, 5*(9), 680-687. doi:10.1038/nchembio.190

Morita, M., Ler, L. W., Fabian, M. R., Siddiqui, N., Mullin, M., Henderson, V. C., . . . Sonenberg, N. (2012). A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development. *Mol Cell Biol, 32*(17), 3585-3593. doi:10.1128/MCB.00455-12

Okumura, F., Zou, W., & Zhang, D. E. (2007). ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. *Genes Dev, 21*(3), 255-260. doi:10.1101/gad.1521607

Olshen, A. B., Hsieh, A. C., Stumpf, C. R., Olshen, R. A., Ruggero, D., & Taylor, B. S. (2013). Assessing gene-level translational control from ribosome profiling. *Bioinformatics, 29*(23), 2995-3002. doi:10.1093/bioinformatics/btt533

Ozgur, S., Basquin, J., Kamenska, A., Filipowicz, W., Standart, N., & Conti, E. (2015). Structure of a Human 4E-T/DDX6/CNOT1 Complex Reveals the Different Interplay of DDX6-Binding Proteins with the CCR4-NOT Complex. *Cell Rep, 13*(4), 703-711. doi:10.1016/j.celrep.2015.09.033

Park, Y. J., Lee, J. M., Shin, S. Y., & Kim, Y. H. (2014). Constitutively active Ras negatively regulates Erk MAP kinase through induction of MAP kinase phosphatase 3 (MKP3) in NIH3T3 cells. *Bmb Reports, 47*(12), 685-690. doi:10.5483/BMBRep.2014.47.12.017

Peter, D., Weber, R., Sandmeir, F., Wohlbold, L., Helms, S., Bawankar, P., . . . Izaurralde, E. (2017). GIGYF1/2 proteins use auxiliary sequences to selectively bind to 4EHP and repress target mRNA expression. *Genes & Development, 31*(11), 1147-1161. doi:10.1101/gad.299420.117

Pfuhlmann, K., Pfluger, P. T., Schriever, S. C., Muller, T. D., Tschop, M. H., & Stemmer, K. (2017). Dual specificity phosphatase 6 deficiency is associated with impaired systemic glucose tolerance and reversible weight retardation in mice. *PLoS One, 12*(9), e0183488. doi:10.1371/journal.pone.0183488

Prior, I. A., Lewis, P. D., & Mattos, C. (2012). A Comprehensive Survey of Ras Mutations in Cancer. *Cancer Research, 72*(10), 2457-2467. doi:10.1158/0008-5472.Can-11-2612

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nature Protocols, 8*(11), 2281-2308. doi:10.1038/nprot.2013.143

Rom, E., Kim, H. C., Gingras, A. C., Marcotrigiano, J., Favre, D., Olsen, H., . . . Sonenberg, N. (1998a). Cloning and characterization of 4EHP, a novel mammalian eIF4E-related cap-binding protein. *Journal of Biological Chemistry, 273*(21), 13104-13109. doi:DOI 10.1074/jbc.273.21.13104

773 Rom, E., Kim, H. C., Gingras, A. C., Marcotrigiano, J., Favre, D., Olsen, H., . . . Sonenberg, N.
774 (1998b). Cloning and characterization of 4EHP, a novel mammalian eIF4E-related
775 cap-binding protein. *J Biol Chem, 273*(21), 13104-13109.
776 Rosettani, P., Knapp, S., Vismara, M. G., Rusconi, L., & Cameron, A. D. (2007). Structures of
777 the human eIF4E homologous protein, h4EHP, in its m7GTP-bound and unliganded
778 forms. *J Mol Biol, 368*(3), 691-705. doi:10.1016/j.jmb.2007.02.019
779 Samatar, A. A., & Poulikakos, P. I. (2014). Targeting RAS-ERK signalling in cancer: promises
780 and challenges. *Nat Rev Drug Discov, 13*(12), 928-942. doi:10.1038/nrd4281
781 Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008).
782 Widespread changes in protein synthesis induced by microRNAs. *Nature,*
783 *455*(7209), 58-63. doi:10.1038/nature07228
784 Shojaee, S., Caeser, R., Buchner, M., Park, E., Swaminathan, S., Hurtz, C., . . . Muschen, M.
785 (2015). Erk Negative Feedback Control Enables Pre-B Cell Transformation and
786 Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. *Cancer Cell,*
787 *28*(1), 114-128. doi:10.1016/j.ccell.2015.05.008
788 Sonenberg, N., & Hinnebusch, A. G. (2009). Regulation of translation initiation in eukaryotes:
789 mechanisms and biological targets. *Cell, 136*(4), 731-745.
790 doi:10.1016/j.cell.2009.01.042
791 Stumpf, C. R., Moreno, M. V., Olshen, A. B., Taylor, B. S., & Ruggero, D. (2013). The
792 Translational Landscape of the Mammalian Cell Cycle. *Molecular Cell, 52*(4), 574-
793 582. doi:10.1016/j.molcel.2013.09.018
794 Suffert, G., Malterer, G., Hausser, J., Viiliainen, J., Fender, A., Contrant, M., . . . Pfeffer, S.
795 (2011). Kaposi's Sarcoma Herpesvirus microRNAs Target Caspase 3 and Regulate
796 Apoptosis. *Plos Pathogens, 7*(12). doi:ARTN e1002405

797 10.1371/journal.ppat.1002405
798 Szostak, E., & Gebauer, F. (2013). Translational control by 3'-UTR-binding proteins. *Brief*
799 *Funct Genomics, 12*(1), 58-65. doi:10.1093/bfgp/els056
800 Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012). A
801 unifying model for mTORC1-mediated regulation of mRNA translation. *Nature,*
802 *485*(7396), 109-113. doi:10.1038/nature11083
803 Uniacke, J., Perera, J. K., Lachance, G., Francisco, C. B., & Lee, S. (2014). Cancer cells exploit
804 eIF4E2-directed synthesis of hypoxia response proteins to drive tumor progression.
805 *Cancer Res, 74*(5), 1379-1389. doi:10.1158/0008-5472.CAN-13-2278
806 Will, M., Qin, A. C., Toy, W., Yao, Z., Rodrik-Outmezguine, V., Schneider, C., . . . Rosen, N.
807 (2014). Rapid induction of apoptosis by PI3K inhibitors is dependent upon their
808 transient inhibition of RAS-ERK signaling. *Cancer Discov, 4*(3), 334-347.
809 doi:10.1158/2159-8290.CD-13-0611
810 Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995). Opposing effects of
811 ERK and JNK-p38 MAP kinases on apoptosis. *Science, 270*(5240), 1326-1331.
812 Yang, Y., Chaerkady, R., Beer, M. A., Mendell, J. T., & Pandey, A. (2009). Identification of miR-
813 21 targets in breast cancer cells using a quantitative proteomic approach.
814 *Proteomics, 9*(5), 1374-1384. doi:10.1002/pmic.200800551
815 Zhang, Z., Kobayashi, S., Borczuk, A. C., Leidner, R. S., Laframboise, T., Levine, A. D., &
816 Halmos, B. (2010). Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated
817 negative feedback mediator of oncogenic ERK signaling in lung cancer cells.
818 *Carcinogenesis, 31*(4), 577-586. doi:10.1093/carcin/bgq020

819

Figure legends

Figure 1 with 1 supplement: 4EHP controls translation of a subset of mRNAs. (***A***) The log2 ratio plot of abundance of ribosome footprints (RFP) and mRNAs in 4EHP-KO vs WT MEFs is shown. R^2 indicates Pearson correlation. (***B***) Comparison of 3´ UTR length of mRNAs up- or downregulated in 4EHP-KO MEFs. p-values: Up vs. Down: 2.26e-22, Up vs. Unchanged: 4.26e-17. (***C***) miRNA-binding sites in the 3´ UTR of mRNAs identified in (A). p-values: Up vs. Down: 0.000019, Up vs. Unchanged: 0.00040. (***D***) miRNA-binding site density (number of miRNA-binding sites per 100-nucleotide of 3' UTR) in mRNA identified in (A). p-values: Up vs. Down: 0.000043, Up vs. Unchanged: 0.0063. (***E***) RNA-immunoprecipitation (RIP) analysis of the association of eIF4E with 4EHP targets in 4EHP-KO MEFs. eIF4E was immunoprecipitated using a monoclonal antibody against eIF4E from WT and 4EHP-KO MEFs. Levels of the indicated mRNAs (normalized to *β-actin* mRNA) in the inputs and eIF4E-bound mRNAs were analyzed by RT–qPCR. Data are mean ± SD (n = 3). The p-value was determined by two-tailed Student's *t*-test: (ns) non-significant, (*) $P < 0.05$; (**) $P < 0.01$; (***) $P < 0.001$.

Figure 2 with 1 supplement: Depletion of 4EHP expression affects cell proliferation, survival, and ERK1/2 phosphorylation. (***A***) Cell proliferation assay. WT and 4EHP-KO MEFs were seeded in 6-well plates and trypsinized after the indicated time points and cell numbers determined using a hematocytometer. Data are mean ± SD (n = 3). (***B***) Cell proliferation assay. U251 cells with stable expression of shCTR (control), sh4EHP#1, and sh4EHP#2 were seeded in 6-well plates. Cells were trypsinized after the indicated time

points and cell numbers determined using a hematocytometer. Data are mean ± SD (n = 3). (***C***) Quantitation of cell death by FACS assay*;* Sub-G population was considered as "Dead" and G0/1, S and G2/M population was combined as "Live". Data are mean ± SD (n = 3). (***D***) WB for the indicated proteins in the WT and 4EHP-KO MEFs. (***E***) Polysome profiling/RT-PCR; RNA was extracted from each fraction (collected as described in *Fig. S2J*), subjected to electrophoresis on agarose gel and visualized, using Ethidium Bromide (EtBr) staining. RT-PCR analyses of total RNA in each fraction was carried out with primers specific for *Dusp6* and *Gapdh* mRNAs. (***F***) WB on the indicated proteins in WT and 4EHP-KO MEFs. (***G***) WB for the indicated proteins in the WT and 4EHP-KO MEFs, expressing a v5-tagged GFP (GFP-v5) or v5-tagged 4EHP (4EHP-v5).

Figure 3 with 1 supplement: 4EHP enables miRNA-mediated silencing of *Dusp6* mRNA. (***A***) RIP analysis of the association of eIF4E with *Dusp6* mRNA in WT and 4EHP-KO MEFs. eIF4E was immunoprecipitated using a monoclonal antibody. Levels of the indicated mRNAs (normalized to *β-actin* mRNA) in the inputs and eIF4E-bound mRNAs were analyzed by RT–qPCR. Data are mean ± SD (n = 3). (***B***) *Top*; Schematic representation of the psiCHECK-FL-*Dusp6* 3´ UTR reporter. *Bottom;* CTR, CNOT1, 4E-T, or 4EHP-knockdown cells were co-transfected with psiCHECK-FL-*Dusp6* 3´ UTR reporter or the psiCHECK reporter (as control) in HEK293T cells. Luciferase activity was measured 24 h after transfection. *Firefly* (*F-Luc*) values were normalized against *Renilla* (*R-Luc*) levels, and repression fold was calculated for the psiCHECK-FL-*Dusp6* 3´ UTR reporter relative to psiCHECK reporter level for each condition. Data are mean ± SD (n = 3). (***C***) The psiCHECK reporter (control) or psiCHECK-RL with truncated fragments of the *Dusp6* 3´ UTR were transfected into the HEK293T cells. Luciferase

activity was measured 24 h after transfection. *R-Luc* values were normalized against *F-Luc* levels, and repression fold was calculated for the psiCHECK-RL-*Dusp6* 3´ UTR reporter relative to psiCHECK reporter level for each condition. Data are mean ± SD (n = 3). (***D***) WB for the indicated proteins in U251 cells transfected with si4EHP or the indicated miRNA inhibitors. (***E***) The psiCHECK reporter (control) or psiCHECK-FL-*Dusp6* 3´ UTR were co-transfected along with the mock or miR-145 inhibitor in the control (CTR) or 4EHP-KO HEK293 cells. Luciferase activity was measured 24 h after transfection. *F-Luc* values were normalized against *R-Luc* levels, and repression fold was calculated relative to the psiCHECK reporter/control inhibitor for each condition. Data are mean ± SD (n = 3). The *p*-values was determined by two-tailed Student's *t*-test: (ns) non-significant, (*) $P < 0.05$; (**) $P < 0.01$; (***) $P < 0.001$.

Figure 4 with 1 supplement: De-repression of DUSP6 in 4EHP-depleted cells impedes on ERK activity and cell proliferation. (***A***) Time course WB analyses of BCI-treated WT and 4EHP-KO MEFs. (***B***) Cell proliferation assay. WT and 4EHP-KO MEFs with stable expression of shCTR, shDusp6#1, and shDusp6#2 were seeded in 6-well plates. Cells were trypsinized after the indicated time points and cell numbers determined using a hematocytometer. Data are mean ± SD (n = 3). (***C)*** WB for the indicated proteins in the WT and 4EHP-KO MEFs, with stable expression of a constitutively active mutant of KRAS (G12V). (***D***) Model of regulation of MAPK/ERK pathway activity by 4EHP through translational control of the *Dusp6* mRNA. Upon phosphorylation by MEK, ERK translocates to the nucleus and activates the *Dusp6* gene. The *Dusp6* transcript is then exported to the cytoplasm and translated. miRNAs control the translation of *Dusp6*

mRNA via the CCR4-NOT/4E-T/4EHP complex and thus regulate the MAPK/ERK pathway activity.

Figure 1—figure supplement 1: Analysis of 4EHP-sensitive mRNAs by ribosome profiling. (***A***) Summary of workflow used to identify 4EHP-sensitive mRNAs by ribosome profiling. (***B***) Correlation between replicates in mRNA-Seq and ribosome profiling datasets. R^2 indicates Pearson correlation. (***C***) Comparison of 5´ UTR length in mRNAs identified by Babel analysis as up- or down-regulated in 4EHP-KO MEFs. p-values: Up vs. Down: 2.68e-06, Up vs. Unchanged: 0.038. (***D***) WB analysis of the indicated protein in the eIF4E RIP assay (related to Fig. 1E and 3A). eIF4E was immunoprecipitated using a monoclonal antibody in WT and 4EHP-KO MEFs. Precipitated proteins were separated by SDS-PAGE and probed with the specified antibodies.

Figure 2—figure supplement 1: Cell proliferation and translational regulation of Dusp6 expression is affected by 4EHP depletion. (***A***) WB for the indicated proteins in the WT and 4EHP-KO MEFs. (***B***) Cell proliferation was assessed using Sulforhodamine B (SRB assay) as described in the "METHODS" section. Data are mean ± SD (n = 3). (***C***) *Top;* Representative cell cycle profiles of the WT and 4EHP-KO MEFs stained with Propidium Iodide and analyzed by FACS. *Bottom;* quantitation of cell cycle profiles. Data are mean ± SD (n = 3). (***D***) WB for the indicated proteins in control and stable 4EHP-knockdown U251 cells. (***E***) WB for the indicated proteins in the control and stable 4EHP-knockdown U87 cells. (***F***) Cell proliferation assay; U87 cells with stable expression of shCTR, sh4EHP#1, and sh4EHP#2 were seeded in 6-well plates. Cells

were trypsinized after the indicated time points and cell numbers determined using a hematocytometer. Data are mean ± SD (n = 3). (***G***) FACS assay. Representative cell cycle profiles of shCTR, sh4EHP#1, and sh4EHP#2 U251 cells stained with Propidium Iodide and analyzed by FACS. (***H***) WB for the indicated proteins in the control and stable 4EHP-knockdown U251 cells. (***I***) WB for the indicated proteins in the control and stable *Dusp6*-knockdown U251 cells. (***J***) Polysome profiling; cytoplasmic extract from WT and 4EHP-KO MEFs was fractioned by centrifugation on a 10–50% sucrose gradient. Fourteen fractions were collected while 254-nm absorbance was recorded. (***K***) WB for the indicated proteins in control (shCTR) and 4EHP-knockdown (sh4EHP) U251 cells. (***L***) WB for the indicated proteins in the control and stable 4EHP-knockdown U251 cells. (***M***) RT-qPCR analysis of *Dusp6* mRNA in shCTR and sh4EHP U251 cells. Values are normalized to *β-actin*. Data are mean ± SD (n = 3). (***N***) RNA stability assay of *Dusp6* mRNA in shCTR and sh4EHP U251 cells. The amount of RNA at different time points was determined by reverse RT-qPCR. Values are normalized to 28S rRNA. Data are mean ± SD (n = 3).

Figure 3—figure supplement 1: Repression of DUSP6 expression by CCR4-NOT complex. (***A***) WB for the indicated proteins in control or siRNA transfected U251 cells. (***B***) Diagram of *Dusp6* mRNA 3´ UTR, predicted miRNA binding sites, pumilio responsive element (PRE), and truncation fragments of the UTR created for cloning into the reporter construct used in Fig. 3C. (***C***) RNA stability assay of *Dusp6* mRNA in Mock and miR-145-inhibitor transfected cells. The quantity of RNA at different time points was determined by reverse RT-qPCR. Values are normalized to 28S rRNA. Data are mean ± SD (n = 3). (***D***) Sequence alignment of 10 cloned PCR products amplified from the

933 genomic segment of 4EHP targeted by 5´-TGAGCTCGTGGGACGGCCGG sgRNA
934 showing the disruption of the coding sequence (related to Figure 3E).

935 **Figure 4—figure supplement 1: DUSP6-mediated repression of ERK activity and**
936 **cell proliferation in 4EHP-depleted cells.** (***A***) Time course analyses of BCI-treated
937 control and 4EHP-knockdown U251 cells by WB for the indicated proteins. (***B***) WB for
938 the indicated proteins in the control or *Dusp6*-knockdown WT and 4EHP-KO MEFs. (***C***)
939 Cell proliferation assay. WT and 4EHP-KO MEFs, with stable expression of a
940 constitutively active mutant KRAS (G12V) were seeded in 6-well plates. Cells were
941 trypsinized after the indicated time points and cell numbers determined using a
942 hematocytometer. Data are mean ± SD (n = 3).

943 **SUPPLEMENTAL INFORMATION**

944 **Supplementary file 1:** mRNAs differentially translated in 4EHP-KO vs. WT MEFs
945 identified by the ribosome profiling assay.

946 **Supplementary file 2.** Dusp6 3´ UTR isolated from U251 human glioblastoma cell line.
947 Highlighted sequence represent the translation stop codon.

948 **Supplementary file 3:** List of primers used in this study.

Figure 1


A
Log2 mRNA (RPKM KO/WT)
Log2 RFP (RPKM KO/WT)
Up
Down
Unchanged
B
Cumulative Distribution
Log2 3´ UTR length
C
Total miRNAs sites / 3´ UTR
D
miRNA sites / 100 bp of 3´ UTR
E
Slc35e1
Klhl21
Tmed7
mRNA / β-actin
WT
KO
input
IP: eIF4E
ns
***
F
Lyar
Iqgap1
Gapdh
*

Figure 1—figure supplement 1









Figure 2


A
MEF
WT
KO
Cell # (x1000)
Day #
B
U251
shCTR
sh4EHP#1
sh4EHP#2
Cell # (x1000)
Day#
C
% of cell population
Live
Dead
***
***
shCTR
sh4EHP #1
sh4EHP #2
D
WT
KO
pERK
ERK
pMEK
MEK
pRPS6
RPS6
4EHP
α-tubulin
E
80S
polysomes
WT
KO
EtBr
Dusp6
Gapdh
F
DUSP6
pERK
ERK
4EHP
α-tubulin
G
GFP-v5
4EHP-v5
Dusp6
4EHP
α-tubulin

Figure 2—figure supplement 1



Figure 3


A
input
RIP: eIF4E
WT
KO
Fold change
ns
**
Dusp6
Dusp7
B
m7Gppp
F-Luc
Dusp6-3´ UTR
poly(A)
psiCheck
psiCheck + Dusp6 3´ UTR
Repression fold
siCTR
siCNOT1
si4E-T
si4EHP
C
m7Gppp
R-Luc
UTR
poly(A)
Repression fold
siCTR
si4EHP
Fragment #
D
miRNA inhibitor
si4EHP
siCTR
miR-124
miR-145
miR-181-a
DUSP6
GAPDH
E
Mock
miR-145 inhibitor
***
Repression fold
Empty
Dusp6 3´ UTR
CTR
4EHP-KO

Figure 3—figure supplement 1







D

```
chr2(+):232,557,937-232,557,976  GTACTCCAGGAGAACCCCCG----------------------------------------------------------------------GCCGTCCCACGAGCT
                      Clone  1  GTACTCCAGGAGAACCCCCGAGTCAAGTTGCCAGCAGGGTTGGTTTTTCCTAAGGCCTCACTCGGCGTGGAGATGGCTGTCTTCGCCGTCCCACGAGCT
                      Clone  2  GTACTCCAGGAGAACCCCCGGTGGCAAGTGTAGCGGTCACGCTGCG...133 nt...TGCGCGCTCGCTCGCTCACTGAGGCCGCCGTCCCACGAGCT
                      Clone  3  GTACTCCAGGAGAACCCCCGAGTCAAGTTGCCAGCAGGGTTGGTTTTTCCTAAGGCCTCACTCGGCGTGGAGATGGCTGTCTTCGCCGTCCCACGAGCT
                      Clone  4  GTACTCCAGGAGAACCCCCGGTGGCAAGTGTAGCGGTCACGCTGCG...133 nt...TGCGCGCTCGCTCGCTCACTGAGGCCGCCGTCCCACGAGCT
                      Clone  5  GTACTCCAGGAGAACCCCCGAGTCAAGTTGCCAGCAGGGTTGGTTTTTCCTAAGGCCTCACTCGGCGTGGAGATGGCTGTCTTCGCCGTCCCACGAGCT
                      Clone  6  GTACTCCAGGAGAACCCCCGAGTCAAGTTGCCAGCAGGGTTGGTTTTTCCTAAGGCCTCACTCGGCGTGGAGATGGCTGTCTTCGCCGTCCCACGAGCT
                      Clone  7  GTACTCCAGGAGAACCCCCGAGTCAAGTTGCCAGCAGGGTTGGTTTTTCCTAAGGCCTCACTCGGCGTGGAGATGGCTGTCTTCGCCGTCCCACGAGCT
                      Clone  8  GTACTCCAGGAGAACCCCCGAGTCAAGTTGCCAGCAGGGTTGGTTTTTCCTAAGGCCTCACTCGGCGTGGAGATGGCTGTCTTCGCCGTCCCACGAGCT
                      Clone  9  GTACTCCAGGAGAACCCCCGAGTCAAGTTGCCAGCAGGGTTGGTTTTTCCTAAGGCCTCACTCGGCGTGGAGATGGCTGTCTTCGCCGTCCCACGAGCT
                      Clone 10  GTACTCCAGGAGAACCCCCGGTGGCAAGTGTAGCGGTCACGCTGCG...133 nt...TGCGCGCTCGCTCGCTCACTGAGGCCGCCGTCCCACGAGCT
```

Figure 4


A
WT
KO
BCI (5μM): - 0.5 h 1 h 2 h - 0.5 h 1 h 2 h
pERK
ERK
DUSP6
4EHP
α-tubulin
B
MEF
WT/shCTR
WT/shDusp6#1
WT/shDusp6#2
KO/shCTR
KO/shDusp6#1
KO/shDusp6#2
Cell # (x1000)
Day #
C
CTR
KRAS (G12V)
WT
KO
WT
KO
pERK
ERK
DUSP6
RAS
4EHP
α-tubulin
D
RAS
RAF
MEK
ERK
DUSP6
4EHP
4E-T
m7G
DDX6
1
6
7
AAAA
9
11
10
miRISC
Dusp6 mRNA
Dusp6
Transcription

Figure 4—figure supplement 1